Briumvi Accelagen Pty Ltd
Product name
Briumvi
Sponsor
Accepted date
Jul-2024
Active ingredients
ublituximab
Proposed indication
For the treatment of relapsing forms of multiple sclerosis
Application type
A (new medicine)
Publication date
Jul-2024